CA2841875C - Combination therapy with an anti - cd19 antibody and a nitrogen mustard - Google Patents

Combination therapy with an anti - cd19 antibody and a nitrogen mustard Download PDF

Info

Publication number
CA2841875C
CA2841875C CA2841875A CA2841875A CA2841875C CA 2841875 C CA2841875 C CA 2841875C CA 2841875 A CA2841875 A CA 2841875A CA 2841875 A CA2841875 A CA 2841875A CA 2841875 C CA2841875 C CA 2841875C
Authority
CA
Canada
Prior art keywords
use according
lymphoma
seq
sequence
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2841875A
Other languages
English (en)
French (fr)
Other versions
CA2841875A1 (en
Inventor
Jutta AMERSDORFER
Stefan Steidl
Mark Winderlich
Susanne KROHN
Lisa Rojkjaer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Priority to CA3137321A priority Critical patent/CA3137321A1/en
Publication of CA2841875A1 publication Critical patent/CA2841875A1/en
Application granted granted Critical
Publication of CA2841875C publication Critical patent/CA2841875C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2841875A 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard Active CA2841875C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3137321A CA3137321A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
EP11177658.9 2011-08-16
US61/523,861 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US61/647,539 2012-05-16
US201261654097P 2012-06-01 2012-06-01
US61/654,097 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3137321A Division CA3137321A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (2)

Publication Number Publication Date
CA2841875A1 CA2841875A1 (en) 2013-02-21
CA2841875C true CA2841875C (en) 2021-11-02

Family

ID=47714801

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2841875A Active CA2841875C (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard
CA3137321A Pending CA3137321A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3137321A Pending CA3137321A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Country Status (24)

Country Link
US (3) US20140255427A1 (enExample)
EP (2) EP2744515B1 (enExample)
JP (1) JP6184952B2 (enExample)
KR (3) KR20200058583A (enExample)
CN (1) CN103732252B (enExample)
AU (1) AU2012296907B2 (enExample)
BR (1) BR112013033919B1 (enExample)
CA (2) CA2841875C (enExample)
CY (1) CY1125122T1 (enExample)
DK (1) DK2744515T3 (enExample)
ES (1) ES2909722T3 (enExample)
HR (1) HRP20220228T1 (enExample)
HU (1) HUE058350T2 (enExample)
IL (1) IL230293B (enExample)
LT (1) LT2744515T (enExample)
MX (1) MX354479B (enExample)
PL (1) PL2744515T3 (enExample)
PT (1) PT2744515T (enExample)
RS (1) RS63238B1 (enExample)
RU (1) RU2625222C2 (enExample)
SG (1) SG10201606785UA (enExample)
SI (1) SI2744515T1 (enExample)
SM (1) SMT202200159T1 (enExample)
WO (1) WO2013024097A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
PL3302550T3 (pl) * 2015-05-26 2020-02-28 Morphosys Ag Kombinacja przeciwciała anty-cd19 i inhibitora kinazy tyrozynowej brutona i jej zastosowania
SI3337506T1 (sl) 2015-08-21 2021-12-31 Morphosys Ag Kombinacije in njihove uporabe
JP7208010B2 (ja) 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
SG11201810159TA (en) * 2016-05-30 2018-12-28 Morphosys Ag Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
WO2018102795A2 (en) 2016-12-02 2018-06-07 University Of Southern California Synthetic immune receptors and methods of use thereof
IL270855B2 (en) 2017-05-31 2023-03-01 Morphosys Ag A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
IL313736A (en) * 2021-12-22 2024-08-01 Incyte Corp Treatment paradigm for CD19 antibody therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
DK1071752T3 (da) * 1998-04-21 2003-10-20 Micromet Ag CD19xCD3-specifikke polypeptider og anvendelsen deraf
HK1043312B (en) * 1999-05-07 2006-07-28 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1814544A4 (en) 2004-11-05 2009-12-02 Cephalon Inc CANCER TREATMENTS
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
JP5825756B2 (ja) * 2006-08-14 2015-12-02 ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． Ｃｄ１９を標的とする最適化抗体
AU2007294575B2 (en) 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US20110274697A1 (en) * 2009-01-16 2011-11-10 Cherry Teresa Thomas Novel uses
SG173654A1 (en) 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
CN102470172B (zh) * 2009-08-14 2014-09-24 罗切格利卡特公司 无岩藻糖基化cd20抗体与氟达拉滨和/或米托蒽醌的联合疗法
MX2012005163A (es) * 2009-11-06 2012-11-22 Infinity Pharmaceuticals Inc Formulaciones orales de un inhibidor de la ruta de hedgehog.

Also Published As

Publication number Publication date
JP6184952B2 (ja) 2017-08-23
HUE058350T2 (hu) 2022-07-28
KR20190107749A (ko) 2019-09-20
NZ617770A (en) 2016-01-29
US20200353077A1 (en) 2020-11-12
KR20140064873A (ko) 2014-05-28
ES2909722T3 (es) 2022-05-10
MX2013014933A (es) 2014-04-16
CN103732252B (zh) 2017-11-10
PT2744515T (pt) 2022-05-19
KR20200058583A (ko) 2020-05-27
WO2013024097A1 (en) 2013-02-21
RS63238B1 (sr) 2022-06-30
SI2744515T1 (sl) 2022-05-31
HRP20220228T1 (hr) 2022-05-13
DK2744515T3 (da) 2022-03-28
US20140255427A1 (en) 2014-09-11
KR102115203B1 (ko) 2020-05-28
CY1125122T1 (el) 2024-12-13
BR112013033919B1 (pt) 2022-11-16
AU2012296907B2 (en) 2017-01-05
LT2744515T (lt) 2022-04-25
SMT202200159T1 (it) 2022-05-12
EP2744515A1 (en) 2014-06-25
RU2625222C2 (ru) 2017-07-12
RU2014103492A (ru) 2015-09-27
SG10201606785UA (en) 2016-10-28
PL2744515T3 (pl) 2022-05-30
JP2014525926A (ja) 2014-10-02
BR112013033919A2 (pt) 2017-12-19
IL230293B (en) 2019-01-31
CA2841875A1 (en) 2013-02-21
CA3137321A1 (en) 2013-02-21
MX354479B (es) 2018-03-07
US20240366756A1 (en) 2024-11-07
CN103732252A (zh) 2014-04-16
EP4062936A1 (en) 2022-09-28
EP2744515B1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US20240366756A1 (en) Combinations and uses thereof
EP3302550B1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2022202800B2 (en) Combinations and uses thereof
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
JP2014525926A5 (enExample)
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
HK40069168A (en) Combinations and uses thereof
HK40023127A (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
NZ617770B2 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240806

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241223